%0 Journal Article
%T Smoldering Multiple Myeloma: Observation Versus Control Versus Cure.
%A Rajkumar SV
%A Bergsagel PL
%A Kumar S
%J Hematol Oncol Clin North Am
%V 38
%N 2
%D 2024 Apr 28
%M 38158241
%F 2.861
%R 10.1016/j.hoc.2023.12.001
%X Smoldering multiple myeloma (SMM) is an intermediate clinical stage in the spectrum of monoclonal plasma cell disorders. It represents a heterogeneous clinically defined condition in which some patients (approximately 50%) have monoclonal gammopathy of undetermined significance (premalignancy), and some (approximately 50%) have multiple myeloma (biologic malignancy). Using specific prognostic factors, patients with SMM, in whom malignant transformation has already likely occurred, can be identified. These patients are considered to have high-risk SMM. Patients with newly diagnosed high-risk SMM are candidates for early intervention with lenalidomide or lenalidomide plus dexamethasone for 2 years, or enrollment in clinical trials.